BioSight
Companies
Adaptive Biotechnologies Corp logo

ADPT

NASDAQSEATTLE, WA
Adaptive Biotechnologies Corp

Adaptive Biotechnologies develops diagnostic and therapeutic products based on immune system data, primarily focused on T-cell analysis through its proprietary immune medicine platform and TCR-antigen binding research. The company currently commercializes clonoSEQ, a diagnostic product, while pursuing development of therapeutic candidates that aim to leverage T-cell mediated responses across multiple disease indications. Adaptive is in early-to-mid stage development for its pipeline therapeutics, while generating revenue from its existing diagnostic offerings and licensing its immune data to collaborators.

Price history not yet available for ADPT.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar